Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Horton, Julie K ^a   Wilson, Samuel H ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Base excision repair; DNA polymerase ; PARP inhibitors; PARP 1; XRCC1

Indexed keywords

8 HYDROXYGUANINE; 8 NITROGUANINE; BLEOMYCIN; DNA DIRECTED DNA POLYMERASE BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; XRCC1 PROTEIN;

CANCER CHEMOTHERAPY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DNA SYNTHESIS; EXCISION REPAIR; HUMAN; HYPERSENSITIVITY; METASTATIC MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84891046100     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00257     Document Type: Short Survey

References (38)

1. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull (2009) 89:23-40. doi: 10.1093/bmb/ldp005
2. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer (2011) 105:1114-22. doi:10.1038/bjc.2011.382
3. Horton JK, Wilson SH. Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res (2013) 11:13-8. doi:10.1158/1541-7786.MCR-12-0512
4. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks. Cell Res (2008) 18:48-63. doi:10.1038/cr.2008.7
5. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J (1999) 342:249-68. doi:10.1042/0264-6021:3420249
6. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol (2012) 84:137-46. doi:10.1016/j.bcp.2012.03.018
7. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res (2003) 31:5526-33. doi:10.1093/nar/gkg761
8. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res (2007) 35:7665-75. doi:10.1093/nar/gkm933
9. Campalans A, Kortulewski T, Amouroux R, Menoni H, Vermeulen W, Radicella JP. Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic Acids Res (2013) 41:3115-29. doi:10.1093/nar/gkt025
10. Mortusewicz O, Fouquerel E, Jean-Christophe A, Leonhardt H, Schreiber V. PARG is recruited to DNA damage sites through poly(ADP-ribose)-and PCNA-dependent mechanisms. Nucleic Acids Res (2011) 39:5045-56. doi:10.1093/nar/gkr099
11. Lavrik OI, Prasad R, Sobol RW, Horton JK, Ackerman EJ, Wilson SH. Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate. Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair. J Biol Chem (2001) 276:25541-8. doi:10.1074/jbc.M102125200
12. Cistulli C, Lavrik OI, Prasad R, Hou E, Wilson SH. AP endonuclease and poly(ADP-ribose) polymerase-1 interact with the same base excision repair intermediate. DNA Repair (2004) 3:581-91. doi:10.1016/j.dnarep.2003.09.012
13. Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res (2012) 72:5588-99. doi:10.1158/0008-5472.CAN-12-2753
14. Heacock ML, Stefanick DF, Horton JK, Wilson SH. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair (2010) 9:929-36. doi:10.1016/j.dnarep.2010.05.007
15. Ruf A, De Murcia G, Schulz GE. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry (1998) 37:3893-900. doi:10.1021/bi972383s
16. Gassman NR, Stefanick DF, Kedar PS, Horton JK, Wilson SH. Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts. PLoS ONE (2012) 7:e49301. doi:10.1371/journal.pone.0049301
17. Horton JK, Stefanick DF, Naron JM, Kedar PS, Wilson SH. Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest following DNA methylating agent exposure. J Biol Chem (2005) 280:15773-85. doi:10.1016/j.dnarep.2008.07.006
18. Delaney CA, Wang L-Z, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res (2000) 6:2860-7.
19. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res (2009) 15:1241-9. doi:10.1158/1078-0432.CCR-08-1095
20. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 14:7917-23. doi:10.1158/1078-0432.CCR-08-1223
21. Bedikian AY, Papadopoulos NE, Kim KB, Hwu W-J, Homsi J, Glass MR, et al. A Phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest (2009) 27:756-63. doi:10.1080/07357900802709159
22. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 71:1191-9. doi:10.1007/s00280-013-2113-1
23. Ahmad R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol (2009) 31:388-96. doi:10.1080/08923970802709197
24. Sobol RW, Horton JK, Kuhn R, Gu H, Singhal RK, Prasad R, et al. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature (1996) 379:183-6. doi:10.1038/379183a0
25. Horton JK, Joyce-Gray DF, Pachkowski BF, Swenberg JA, Wilson SH. Hypersensitivity of DNA polymerase β null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair (2003) 2:27-48. doi:10.1016/S1568-7864(02)00184-2
26. Sobol RW, Prasad R, Evenski A, Baker A, Yang X-P, Horton JK, et al. The lyase activity of the DNA repair protein β-polymerase protects from DNA-damage-induced cytotoxicity. Nature (2000) 405:807-10. doi:10.1038/35015598
27. Lan L, Nakajima S, Oohata Y, Takao M, Okano S, Masutani M, et al. In situ analysis of repair processes for oxidative DNA damage in mammalian cells. Proc Natl Acad Sci USA (2004) 101:13738-43. doi:10.1073/pnas.0406048101
28. Horton J, Stefanick D, Gassman N, Williams J, Gabel S, Cuneo MJ, et al. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage. DNA Repair (2013) 12:774-85. doi:10.1016/j.dnarep.2013.06.004
29. Wong H-K, Wilson DM III. XRCC1 and DNA polymerase β interaction contributes to cellular alkylating-agent resistance and single-strand break repair. J Cell Biochem (2005) 95:794-804. doi:10.1002/jcb.20448
30. Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol (2002) 22:2556-63. doi:10.1128/MCB.22.8.2556-2563.2002
31. Kubota Y, Horiuchi S. Independent roles of XRCC1's two BRCT motifs in recovery from methylation damage. DNA Repair (2003) 2:407-15. doi:10.1016/S1568-7864(02)00242-2
32. Starcevic D, Dalal S, Sweasy JB. Is there a link between DNA polymerase β and cancer? Cell Cycle (2004) 3:998-1001. doi:10.4161/cc.3.8.1062
33. An CL, Chen D, Makridakis NM. Systematic biochemical analysis of somatic missense mutations in DNA polymerase beta found in prostate cancer reveal alteration of enzymatic function. Hum Mutat (2011) 32:415-23. doi:10.1002/humu.21465
34. Cuneo MJ, London RE. Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase β binding affinity. Proc Natl Acad Sci USA (2010) 107:6805-10. doi:10.1073/pnas.0914077107
35. Hecht SM. Bleomycin: new perspectives on the mechanism of action. J Nat Prod (1999) 63:158-68. doi:10.1021/np990549f
36. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443
37. Farmer H, Mccabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-21. doi:10.1038/nature03445
38. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 10:1192-9. doi:10.4161/cc.10.8.15273